Browse

You are looking at 1 - 10 of 20 items

Yasufumi Seki Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Yasufumi Seki in
Google Scholar
PubMed
Close
,
Satoshi Morimoto Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Satoshi Morimoto in
Google Scholar
PubMed
Close
,
Naohiro Yoshida Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Naohiro Yoshida in
Google Scholar
PubMed
Close
,
Kanako Bokuda Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Kanako Bokuda in
Google Scholar
PubMed
Close
,
Nobukazu Sasaki Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Nobukazu Sasaki in
Google Scholar
PubMed
Close
,
Midori Yatabe Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Midori Yatabe in
Google Scholar
PubMed
Close
,
Junichi Yatabe Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Junichi Yatabe in
Google Scholar
PubMed
Close
,
Daisuke Watanabe Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Daisuke Watanabe in
Google Scholar
PubMed
Close
,
Satoru Morita Departments of Diagnostic Imaging and Nuclear Medicine, Tokyo, Japan

Search for other papers by Satoru Morita in
Google Scholar
PubMed
Close
,
Keisuke Hata Departments of Urology, Kidney Center, Tokyo, Japan

Search for other papers by Keisuke Hata in
Google Scholar
PubMed
Close
,
Tomoko Yamamoto Departments of Surgical Pathology, Tokyo Women’s Medical University, Tokyo, Japan

Search for other papers by Tomoko Yamamoto in
Google Scholar
PubMed
Close
,
Yoji Nagashima Departments of Surgical Pathology, Tokyo Women’s Medical University, Tokyo, Japan

Search for other papers by Yoji Nagashima in
Google Scholar
PubMed
Close
, and
Atsuhiro Ichihara Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Atsuhiro Ichihara in
Google Scholar
PubMed
Close

Summary

Primary aldosteronism (PA) is more common than expected. Aberrant adrenal expression of luteinizing hormone (LH) receptor in patients with PA has been reported; however, its physiological role on the development of PA is still unknown. Herein, we report two unique cases of PA in patients with untreated Klinefelter’s syndrome, characterized as increased serum LH, suggesting a possible contribution of the syndrome to PA development. Case 1 was a 39-year-old man with obesity and hypertension since his 20s. His plasma aldosterone concentration (PAC) and renin activity (PRA) were 220 pg/mL and 0.4 ng/mL/h, respectively. He was diagnosed as having bilateral PA by confirmatory tests and adrenal venous sampling (AVS). Klinefelter’s syndrome was suspected as he showed gynecomastia and small testes, and it was confirmed on the basis of a low serum total testosterone level (57.3 ng/dL), high serum LH level (50.9 mIU/mL), and chromosome analysis. Case 2 was a 28-year-old man who had untreated Klinefelter’s syndrome diagnosed in his childhood and a 2-year history of hypertension and hypokalemia. PAC and PRA were 247 pg/mL and 0.3 ng/mL/h, respectively. He was diagnosed as having a 10 mm-sized aldosterone-producing adenoma (APA) by AVS. In the APA, immunohistochemical analysis showed co-expression of LH receptor and CYP11B2. Our cases of untreated Klinefelter’s syndrome complicated with PA suggest that increased serum LH levels and adipose tissues, caused by primary hypogonadism, could contribute to PA development. The possible complication of PA in hypertensive patients with Klinefelter’s syndrome should be carefully considered.

Learning points:

  • The pathogenesis of primary aldosteronism is still unclear.

  • Expression of luteinizing hormone receptor has been reported in aldosterone-producing adenoma.

  • Serum luteinizing hormone, which is increased in patients with Klinefelter’s syndrome, might contribute to the development of primary aldosteronism.

Open access
Hui Yi Ng Department of Clinical Medicine, Level 4, Macquarie University, 2 Technology Place, Macquarie University, New South Wales, Australia

Search for other papers by Hui Yi Ng in
Google Scholar
PubMed
Close
,
Divya Namboodiri Department of Clinical Medicine, Level 4, Macquarie University, 2 Technology Place, Macquarie University, New South Wales, Australia

Search for other papers by Divya Namboodiri in
Google Scholar
PubMed
Close
,
Diana Learoyd University of Sydney, Faculty of Medicine and Health, Northern Clinical School, Reserve Road St Leonards, New South Wales, Australia

Search for other papers by Diana Learoyd in
Google Scholar
PubMed
Close
,
Andrew Davidson Department of Neurosurgery, Level 2, Macquarie University, 2 Technology Place Macquarie University, New South Wales, Australia

Search for other papers by Andrew Davidson in
Google Scholar
PubMed
Close
,
Bernard Champion Department of Clinical Medicine, Level 4, Macquarie University, 2 Technology Place, Macquarie University, New South Wales, Australia

Search for other papers by Bernard Champion in
Google Scholar
PubMed
Close
, and
Veronica Preda Department of Clinical Medicine, Level 4, Macquarie University, 2 Technology Place, Macquarie University, New South Wales, Australia

Search for other papers by Veronica Preda in
Google Scholar
PubMed
Close

Summary

Co-secreting thyrotropin/growth hormone (GH) pituitary adenomas are rare; their clinical presentation and long-term management are challenging. There is also a paucity of long-term data. Due to the cell of origin, these can behave as aggressive tumours. We report a case of a pituitary plurihormonal pit-1-derived macroadenoma, with overt clinical hyperthyroidism and minimal GH excess symptoms. The diagnosis was confirmed by pathology showing elevated thyroid and GH axes with failure of physiological GH suppression, elevated pituitary glycoprotein hormone alpha subunit (αGSU) and macroadenoma on imaging. Pre-operatively the patient was rendered euthyroid with carbimazole and underwent successful transphenoidal adenomectomy (TSA) with surgical cure. Histopathology displayed an elevated Ki-67 of 5.2%, necessitating long-term follow-up.

Learning points:

  • Thyrotropinomas are rare and likely under-diagnosed due to under-recognition of secondary hyperthyroidism.

  • Thyrotropinomas and other plurihormonal pit-1-derived adenomas are more aggressive adenomas according to WHO guidelines.

  • Co-secretion occurs in 30% of thyrotropinomas, requiring diligent investigation and long-term follow-up of complications.

Open access
Yang Timothy Du Endocrine and Metabolic Unit, Royal Adelaide Hospital

Search for other papers by Yang Timothy Du in
Google Scholar
PubMed
Close
,
Lynette Moore School of Medicine, University of Adelaide
SA Pathology, Women’s and Children’s Hospital

Search for other papers by Lynette Moore in
Google Scholar
PubMed
Close
,
Nicola K Poplawski Adult Genetics Unit, Royal Adelaide Hospital

Search for other papers by Nicola K Poplawski in
Google Scholar
PubMed
Close
, and
Sunita M C De Sousa Endocrine and Metabolic Unit, Royal Adelaide Hospital
School of Medicine, University of Adelaide
Adult Genetics Unit, Royal Adelaide Hospital
Center for Cancer Biology, SA Pathology and University of South Australia Alliance, Adelaide, South Australia, Australia

Search for other papers by Sunita M C De Sousa in
Google Scholar
PubMed
Close

Summary

A 26-year-old man presented with a combination of permanent neonatal diabetes due to pancreatic aplasia, complex congenital heart disease, central hypogonadism and growth hormone deficiency, structural renal abnormalities with proteinuria, umbilical hernia, neurocognitive impairment and dysmorphic features. His older brother had diabetes mellitus due to pancreatic hypoplasia, complex congenital heart disease, hypospadias and umbilical hernia. Their father had an atrial septal defect, umbilical hernia and diabetes mellitus diagnosed incidentally in adulthood on employment screening. The proband’s paternal grandmother had a congenital heart defect. Genetic testing of the proband revealed a novel heterozygous missense variant (Chr18:g.19761441T>C, c.1330T>C, p.Cys444Arg) in exon 4 of GATA6, which is class 5 (pathogenic) using American College of Medical Genetics and Genomics guidelines and is likely to account for his multisystem disorder. The same variant was detected in his brother and father, but not his paternal grandmother. This novel variant of GATA6 likely occurred de novo in the father with autosomal dominant inheritance in the proband and his brother. The case is exceptional as very few families with monogenic diabetes due to GATA6 mutations have been reported to date and we describe a new link between GATA6 and renal pathology.

Learning points:

  • Monogenic diabetes should be suspected in patients presenting with syndromic features, multisystem congenital disease, neonatal-onset diabetes and/or a suggestive family history.

  • Recognition and identification of genetic diabetes may improve patient understanding and empowerment and allow for better tailored management.

  • Identification of a genetic disorder may have important implications for family planning.

Open access
M A Shehab Department of Endocrinology, BSMMU, Dhaka, Bangladesh

Search for other papers by M A Shehab in
Google Scholar
PubMed
Close
,
Tahseen Mahmood Department of Endocrinology, BSMMU, Dhaka, Bangladesh

Search for other papers by Tahseen Mahmood in
Google Scholar
PubMed
Close
,
M A Hasanat Department of Endocrinology, BSMMU, Dhaka, Bangladesh

Search for other papers by M A Hasanat in
Google Scholar
PubMed
Close
,
Md Fariduddin Department of Endocrinology, BSMMU, Dhaka, Bangladesh

Search for other papers by Md Fariduddin in
Google Scholar
PubMed
Close
,
Nazmul Ahsan Department of Genetic Engineering & Biotechnology, University of Dhaka, Dhaka, Bangladesh

Search for other papers by Nazmul Ahsan in
Google Scholar
PubMed
Close
,
Mohammad Shahnoor Hossain Department of Genetic Engineering & Biotechnology, University of Dhaka, Dhaka, Bangladesh

Search for other papers by Mohammad Shahnoor Hossain in
Google Scholar
PubMed
Close
,
Md Shahdat Hossain Department of Genetic Engineering & Biotechnology, University of Dhaka, Dhaka, Bangladesh

Search for other papers by Md Shahdat Hossain in
Google Scholar
PubMed
Close
, and
Sharmin Jahan Department of Endocrinology, BSMMU, Dhaka, Bangladesh

Search for other papers by Sharmin Jahan in
Google Scholar
PubMed
Close

Summary

Congenital adrenal hyperplasia (CAH) due to the three-beta-hydroxysteroid-dehydrogenase (3β-HSD) enzyme deficiency is a rare autosomal recessive disorder presenting with sexual precocity in a phenotypic male. Klinefelter syndrome (KS) is the most common sex chromosome aneuploidy presenting with hypergonadotropic hypogonadism in a male. However, only a handful of cases of mosaic KS have been described in the literature. The co-existence of mosaic KS with CAH due to 3β-HSD enzyme deficiency portrays a unique diagnostic paradox where features of gonadal androgen deficiency are masked by simultaneous adrenal androgen excess. Here, we report a 7-year-old phenotypic male boy who, at birth presented with ambiguous genitalia, probably a microphallus with penoscrotal hypospadias. Later on, he developed accelerated growth with advanced bone age, premature pubarche, phallic enlargement and hyperpigmentation. Biochemically, the patient was proven to have CAH due to 3β-HSD deficiency. However, the co-existence of bilateral cryptorchidism made us to consider the possibility of hypogonadism as well, and it was further explained by concurrent existence of mosaic KS (47,XXY/46,XX). He was started on glucocorticoid and mineralocorticoid replacement and underwent right-sided orchidopexy on a later date. He showed significant clinical and biochemical improvement on subsequent follow-up. However, the declining value of serum testosterone was accompanied by rising level of FSH thereby unmasking hypergonadotropic hypogonadism due to mosaic KS. In future, we are planning to place him on androgen replacement as well.

Learning points:

  • Ambiguous genitalia with subsequent development of sexual precocity in a phenotypic male points towards some unusual varieties of CAH.

  • High level of serum testosterone, adrenal androgen, plasma ACTH and low basal cortisol are proof of CAH, whereas elevated level of 17-OH pregnenolone is biochemical marker of 3β-HSD enzyme deficiency.

  • Final diagnosis can be obtained with sequencing of HSD3B2 gene showing various mutations.

  • Presence of bilateral cryptorchidism in such a patient may be due to underlying hypogonadism.

  • Karyotyping in such patient may rarely show mosaic KS (47,XXY/46,XX) and there might be unmasking of hypergonadotropic hypogonadism resulting from adrenal androgen suppression from glucocorticoid treatment.

Open access
Laura Hamilton Adams Department of Endocrinology, Diabetes, and Metabolism, University of Kentucky, Lexington, Kentucky, USA

Search for other papers by Laura Hamilton Adams in
Google Scholar
PubMed
Close
and
Derick Adams Department of Endocrinology, Diabetes, and Metabolism, University of Kentucky, Lexington, Kentucky, USA

Search for other papers by Derick Adams in
Google Scholar
PubMed
Close

Summary

Co-secreting TSH and growth hormone pituitary adenomas are rare. We present a case of a 55-year-old woman who presented with symptoms of neck fullness. Ultrasound revealed multiple thyroid nodules and examination revealed several clinical features of acromegaly. She was found to have a co-secreting TSH and growth hormone pituitary macroadenoma. She underwent surgical resection followed by gamma knife radiation, which resulted in complete remission of her TSH and GH-secreting adenoma.

Learning points:

  • TSH-secreting pituitary adenomas are rare and about one-third co-secrete other hormones.

  • Thyroid nodules are common in acromegaly and can be the presenting sign of a growth hormone-secreting pituitary adenoma.

  • In the workup of acromegaly, assessment of other pituitary hormones is essential, even in the absence of symptoms of other pituitary hormone dysfunction.

  • Complete remission of co-secreting GH and TSH pituitary macroadenomas is possible with surgery and radiation alone.

Open access
Yang Timothy Du Department of Diabetes and Endocrinology, Flinders Medical Centre, Bedford Park, South Australia, Australia

Search for other papers by Yang Timothy Du in
Google Scholar
PubMed
Close
,
Angus Rutter School of Medicine, Flinders University, Bedford Park, South Australia, Australia

Search for other papers by Angus Rutter in
Google Scholar
PubMed
Close
, and
Jui T Ho Department of Diabetes and Endocrinology, Flinders Medical Centre, Bedford Park, South Australia, Australia

Search for other papers by Jui T Ho in
Google Scholar
PubMed
Close

Summary

A 40-year-old man with achondroplasia presented with symptoms of hypogonadism, low libido and gynaecomastia. He was found to have hypergonadotropic hypogonadism, and karyotype and fluorescent in situ hybridisation analysis showed SRY-positive 46, XX disorder of sex development (DSD). He was tested to have the common activating mutation of the FGFR3 gene implicated in achondroplasia, indicating that he had the two rare conditions independently, with an extremely low incidence of 1 in 400 million. This, to the best of our knowledge, is the first report of an individual having these two rare conditions concurrently. This case highlights that individuals with achondroplasia should have normal sexual development, and in those presenting with incomplete sexual maturation or symptoms of hypogonadism should prompt further evaluation. We also propose a plausible link between achondroplasia and 46, XX DSD through the intricate interactions between the SRY, SOX9 and FGFR9 gene pathways.

Learning points:

  • The SOX9 and FGF9 genes, which are upregulated by the SRY gene, are important in both sex determination in the embryo, as well as endochondral bone growth.

  • Patients with achondroplasia should have normal sexual development and function in the absence of other confounding factors.

  • Patients with achondroplasia who present with symptoms and signs of abnormal sexual development and/or hypogonadism should be appropriately investigated for other causes.

Open access
Syed Ali Imran Division of Endocrinology and Metabolism, Dalhousie University, Halifax, Nova Scotia, Canada

Search for other papers by Syed Ali Imran in
Google Scholar
PubMed
Close
,
Khaled A Aldahmani Division of Endocrinology, Tawam Hospial, Al-Ain, UAE

Search for other papers by Khaled A Aldahmani in
Google Scholar
PubMed
Close
,
Lynette Penney Department of Pediatrics, Tawam Hospial, Al-Ain, UAE

Search for other papers by Lynette Penney in
Google Scholar
PubMed
Close
,
Sidney E Croul Department of Pathology, Tawam Hospial, Al-Ain, UAE

Search for other papers by Sidney E Croul in
Google Scholar
PubMed
Close
,
David B Clarke Department of Neurosurgery, Dalhousie University, Halifax, Nova Scotia, Canada

Search for other papers by David B Clarke in
Google Scholar
PubMed
Close
,
David M Collier Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by David M Collier in
Google Scholar
PubMed
Close
,
Donato Iacovazzo Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Donato Iacovazzo in
Google Scholar
PubMed
Close
, and
Márta Korbonits Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close

Summary

Early-onset acromegaly causing gigantism is often associated with aryl-hydrocarbon-interacting receptor protein (AIP) mutation, especially if there is a positive family history. A15y male presented with tiredness and visual problems. He was 201 cm tall with a span of 217 cm. He had typical facial features of acromegaly, elevated IGF-1, secondary hypogonadism and a large macroadenoma. His paternal aunt had a history of acromegaly presenting at the age of 35 years. Following transsphenoidal surgery, his IGF-1 normalized and clinical symptoms improved. He was found to have a novel AIP mutation destroying the stop codon c.991T>C; p.*331R. Unexpectedly, his father and paternal aunt were negative for this mutation while his mother and older sister were unaffected carriers, suggesting that his aunt represents a phenocopy.

Learning points:

  • Typical presentation for a patient with AIP mutation with excess growth and eunuchoid proportions.

  • Unusual, previously not described AIP variant with loss of the stop codon.

  • Phenocopy may occur in families with a disease-causing germline mutation.

Open access
Ken Takeshima First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Ken Takeshima in
Google Scholar
PubMed
Close
,
Hiroyuki Ariyasu First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Hiroyuki Ariyasu in
Google Scholar
PubMed
Close
,
Tatsuya Ishibashi First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Tatsuya Ishibashi in
Google Scholar
PubMed
Close
,
Shintaro Kawai First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Shintaro Kawai in
Google Scholar
PubMed
Close
,
Shinsuke Uraki First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Shinsuke Uraki in
Google Scholar
PubMed
Close
,
Jinsoo Koh Department of Neurology, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Jinsoo Koh in
Google Scholar
PubMed
Close
,
Hidefumi Ito Department of Neurology, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Hidefumi Ito in
Google Scholar
PubMed
Close
, and
Takashi Akamizu First Department of Internal Medicine, Wakayama Medical University, Wakayama,, Japan

Search for other papers by Takashi Akamizu in
Google Scholar
PubMed
Close

Summary

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disease affecting muscles, the eyes and the endocrine organs. Diabetes mellitus and primary hypogonadism are endocrine manifestations typically seen in patients with DM1. Abnormalities of hypothalamic–pituitary–adrenal (HPA) axis have also been reported in some DM1 patients. We present a case of DM1 with a rare combination of multiple endocrinopathies; diabetes mellitus, a combined form of primary and secondary hypogonadism, and dysfunction of the HPA axis. In the present case, diabetes mellitus was characterized by severe insulin resistance with hyperinsulinemia. Glycemic control improved after modification of insulin sensitizers, such as metformin and pioglitazone. Hypogonadism was treated with testosterone replacement therapy. Notably, body composition analysis revealed increase in muscle mass and decrease in fat mass in our patient. This implies that manifestations of hypogonadism could be hidden by symptoms of myotonic dystrophy. Our patient had no symptoms associated with adrenal deficiency, so adrenal dysfunction was carefully followed up without hydrocortisone replacement therapy. In this report, we highlight the necessity for evaluation and treatment of multiple endocrinopathies in patients with DM1.

Learning points:

  • DM1 patients could be affected by a variety of multiple endocrinopathies.

  • Our patients with DM1 presented rare combinations of multiple endocrinopathies; diabetes mellitus, combined form of primary and secondary hypogonadism and dysfunction of HPA axis.

  • Testosterone treatment of hypogonadism in patients with DM1 could improve body composition.

  • The patients with DM1 should be assessed endocrine functions and treated depending on the degree of each endocrine dysfunction.

Open access
Usman Javaid Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Usman Javaid in
Google Scholar
PubMed
Close
,
Vikram Lal Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Vikram Lal in
Google Scholar
PubMed
Close
,
Catherine Napier Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK

Search for other papers by Catherine Napier in
Google Scholar
PubMed
Close
,
Alison Burbridge Department of Neurorehabilitation, Northumbria, Tyne & Wear NHS Trust, Newcastle-upon-Tyne, UK

Search for other papers by Alison Burbridge in
Google Scholar
PubMed
Close
, and
Richard Quinton Department of Endocrinology, Newcastle-upon-Tyne Hospitals, Newcastle upon Tyne, UK
Institute of Genetic Medicine, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK

Search for other papers by Richard Quinton in
Google Scholar
PubMed
Close

Hypogonadal men may experience intense vasomotor symptoms, and vasomotor sweating can occasionally be associated with profound fluid losses. We describe a 37-year-old male, who exhibited persistent hypovolaemic hypernatraemia that was challenging to treat despite a continuous high fluid input (>4–5 L/day). He was noted to have drenching sweats and normochromic anaemia. He had recent traumatic head injury, which resulted in neurocognitive dysfunction, so pituitary function tests were done which showed primary hypogonadism. After exclusion of all other possible causes of excess sweating, hypernatraemia and anaemia, a trial of testosterone therapy was instituted. Sweating dramatically ceased within hours of his first testosterone injection, hydration status normalised within days and anaemia and neurocognitive function progressively improved with continued testosterone replacement. This case demonstrates how, in a susceptible individual, hypovolaemic hypernatraemia can arise from insensible cutaneous fluid loss through eccrine sweating, mediated by vasomotor symptoms of untreated hypogonadism. Although this scenario has not been described in the literature, we felt it needed to be shared with the wider medical community because of how the diagnosis and treatment utterly transformed this patient’s functional status and outcome.

Learning points:

  • Hypogonadal men may experience intense vasomotor symptoms and vasomotor sweating can occasionally be associated with profound fluid losses.

  • Whether or not there is also hyperosmolar hypernatraemia, clinicians should always consider the possibility of underlying hypogonadism in men with normocytic anaemia and excessive sweating.

  • Androgen (testosterone) replacement in hypogonadal men can have a dramatic effect on vasomotor sweating and hot flushes.

Open access
Ahmad Haider Private Urology Practice, Bremerhaven, Germany

Search for other papers by Ahmad Haider in
Google Scholar
PubMed
Close
,
Karim S Haider Private Urology Practice, Bremerhaven, Germany

Search for other papers by Karim S Haider in
Google Scholar
PubMed
Close
, and
Farid Saad Global Medical Affairs Andrology, Bayer AG, Berlin, Germany
Research Department, Gulf Medical University, Ajman, UAE

Search for other papers by Farid Saad in
Google Scholar
PubMed
Close

Summary

In daily practice, clinicians are often confronted with obese type 2 diabetes mellitus (T2DM) patients for whom the treatment plan fails and who show an inadequate glycemic control and/or no sustainable weight loss. Untreated hypogonadism can be the reason for such treatment failure. This case describes the profound impact testosterone therapy can have on a male hypogonadal patient with metabolic syndrome, resulting in a substantial and sustained loss of body weight, pronounced improvement of all critical laboratory values and finally complete remission of diabetes.

Learning points:

  • Hypogonadism occurs frequently in men with T2DM.

  • In case of pronounced abdominal fat deposition and T2DM, the male patient should be evaluated for testosterone deficiency.

  • Untreated hypogonadism can complicate the successful treatment of patients with T2DM.

  • Under testosterone therapy, critical laboratory values are facilitated to return back to normal ranges and even complete remission of diabetes can be achieved.

Open access